Update on the use of etanercept across a spectrum of rheumatoid disorders
Bernard CombeService d’Immuno-Rhumatologie, Montpellier, FranceAbstract: Etanercept is a soluble TNF receptor p75 fusion protein which is approved for subcutaneous use (50 mg weekly) in the treatment of patients with active rheumatoid arthritis (RA), juvenile RA, ankylosing spondylitis...
Saved in:
| Main Author: | |
|---|---|
| Format: | article |
| Language: | EN |
| Published: |
Dove Medical Press
2008
|
| Subjects: | |
| Online Access: | https://doaj.org/article/34d4e5cc2b404c0888c6180605d3f83d |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Be the first to leave a comment!